Tailoring adjuvant treatments for the individual patient with luminal breast cancer

Hematology/Oncology Clinics of North America

Volumn 27, Issue 4, 2013, Pages 703-714

  Munzone, Elisabetta ^a   Curigliano, Giuseppe ^a   Colleoni, Marco ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Adjuvant therapy; Breast cancer; Endocrine therapy; Gene assay; Luminal A; Luminal B

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EVEROLIMUS; EXEMESTANE; FLUOROURACIL; KI 67 ANTIGEN; LETROZOLE; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN; TRIPTORELIN;

BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LUMINAL BREAST CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ADJUVANT THERAPY; BREAST CANCER; ENDOCRINE THERAPY; GENE ASSAY; LUMINAL A; LUMINAL B;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS;

EID: 84881311576     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2013.05.012     Document Type: Review

References (55)

1. Goldhirsch A., Ingle J.N., Gelber R.D., et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol 2009, 20(8):1319-1329.
2. Goldhirsch A., Wood W.C., Coates A.S., et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011, 22(8):1736-1747.
3. Albain K.S., Barlow W.E., Shak S., et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010, 11(1):55-65.
4. Hammond M.E., Hayes D.F., Dowsett M., et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. JClin Oncol 2010, 28(16):2784-2795.
5. Dowsett M., Nielsen T.O., A'Hern R., International Ki-67 in Breast Cancer Working Group, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. JNatl Cancer Inst 2011, 103(22):1656-1664.
6. Paik S., Tang G., Shak S., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. JClin Oncol 2006, 24(23):3726-3734.
7. Cardoso F., van't Veer L., Rutgers E., et al. Clinical application of the 70-gene profile: the MINDACT trial. JClin Oncol 2008, 26:729-735.
8. Aebi S., Sun Z., Braun D., et al. Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX. Ann Oncol 2011, 22:1981-1987.
9. Viale G., Regan M.M., Maiorano E., et al. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors-International Breast Cancer Study Group. JClin Oncol 2008, 26:1404-1410.
10. Colleoni M., Cole B.F., Viale G., et al. Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. JClin Oncol 2010, 28:2966-2973.
11. Hayes D.F. Targeting adjuvant chemotherapy: a good idea that needs to be proven!. JClin Oncol 2012, 30(12):1264-1267.
12. Cheang M.C., Chia S.K., Voduc D., et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. JNatl Cancer Inst 2009, 101(10):736-750.
13. Nielsen TO, Polley MY, Leung SC, etal. An international Ki-67 reproducibility study. Presented at the 35th San Antonio Breast Cancer Symposium. December 4-8, 2012 [abstract S4-6].
14. de Azambuja E., Cardoso F., de Castro G., et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007, 96(10):1504-1513.
15. Prat A., Cheang M.C., Martín M., et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal a breast cancer. JClin Oncol 2013, 31(2):203-209.
16. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. Early Breast Cancer Trialists' Collaborative Group.
17. Davies C., Pan H., Godwin J., et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2012, pii:S0140-6736(12) 61963-1. [Epub ahead of print].
18. Zickl L., Francis P., Fleming G., et al. SOFT and TEXT: trials of tamoxifen and exemestane with and without ovarian function suppression for premenopausal women with hormone receptor-positive early breast cancer. Cancer Res 2012, 72(Suppl 24). [abstract nr OT2-2-01].
19. Goss P.E., Ingle J.N., Pater J.L., et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. JClin Oncol 2008, 26(12):1948-1955.
20. Gnant M., Filipits M., Dubsky P., et al. Predicting risk for late metastasis: the pam50 risk of recurrence (ror) score after 5 years of endocrine therapy in postmenopausal women with hr+ early breast cancer: a study on 1,478 patients from the abcsg-8 trial. Ann Oncol 2013, 24(Suppl 3):iii29-iii37. [Abstract 530].
21. Colleoni M., Rotmensz N., Maisonneuve P., et al. Outcome of special types of luminal breast cancer. Ann Oncol 2012, 23(6):1428-1436.
22. Diab S.G., Clark G.M., Osborne C.K., et al. Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. JClin Oncol 1999, 17:1442-1448.
23. Rakha E.A., Lee A.H., Evans A.J., et al. Tubular carcinoma of the breast: further evidence to support its excellent prognosis. JClin Oncol 2010, 28:99-104.
24. Cristofanilli M., Gonzalez-Angulo A., Sneige N., et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and surgical outcomes. JClin Oncol 2005, 23:41-48.
25. Tubiana-Hulin M., Stevens D., Lasry S., et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol 2006, 17:1228-1233.
26. Iorfida M., Maiorano E., Orvieto E., et al. Invasive lobular breast cancer: subtypes and outcome. Breast Cancer Res Treat 2012, 133(2):713-723.
27. Cui X., Schiff R., Arpino G., et al. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. JClin Oncol 2005, 23:7721-7735.
28. Rakha E.A., El-Sayed M.E., Green A.R., et al. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. JClin Oncol 2007, 25:4772-4778.
29. Creighton C.J., Kent Osborne C., van de Vijver M.J., et al. Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat 2009, 114:287-299.
30. Cancello G., Maisonneuve P., Rotmensz N., et al. Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. Ann Oncol 2013, 24(3):661-668.
31. Bauer K., Parise C., Caggiano V. Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer. BMC Cancer 2010, 10:228.
32. Dunnwald L., Rossing M., Li C. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 2007, 9:R6.
33. Grann V.R., Troxel A.B., Zojwalla N.J., et al. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer 2005, 103:2241-2251.
34. Mohsin S.K., Weiss H., Havighurst T., et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol 2004, 17:1545-1554.
35. Bardou V.J., Arpino G., Elledge R.M., et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. JClin Oncol 2003, 21:1973-1979.
36. Stuart-Harris R., Caldas C., Pinder S.E., et al. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 2008, 17(4):323-334.
37. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012, 379(9814):432-444. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
38. Pagani O., O'Neill A., Castiglione M., et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 1998, 34:632-640.
39. Goldhirsch A., Gelber R.D., Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. Ann Oncol 1990, 1:183-188.
40. Scottish Cancer Trials Breast Group and ICRF Breast Unit. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Lancet 1993, 341:1293-1298.
41. Swain S.M., Jeong J.H., Geyer C.E., et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. NEngl J Med 2010, 362:2053-2065.
42. Mamounas E.P., Bryant J., Lembersky B., et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. JClin Oncol 2005, 23:3686-3696.
43. Henderson I.C., Berry D.A., Demetri G.D., et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. JClin Oncol 2003, 21:976-983.
44. Cheang M.C., Voduc K.D., Tu D., et al. Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. Clin Cancer Res 2012, 18:2402-2412.
45. Osborne C.K. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 1998, 51(3):227-238.
46. Osborne C.K., Neven P., Dirix L.Y., et al. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res 2011, 17(5):1147-1159.
47. Baselga J., Campone M., Piccart M., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. NEngl J Med 2012, 366(6):520-529.
48. Shou J., Massarweh S., Osborne C.K., et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. JNatl Cancer Inst 2004, 96(12):926-935.
49. Peyrat J., Louchez M., Lefebvre J., et al. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 1993, 29:492-497.
50. Law J.H., Habibi G., Hu K., et al. Phosphorylated insulin-like growth factor-I/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 2008, 68:10238-10246.
51. Robertson J.F., Ferrero J.M., Bourgeois H., et al. Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. Lancet Oncol 2013, 14(3):228-235.
52. Miller T.W., Balko J.M., Arteaga C.L. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. JClin Oncol 2011, 29:4452-4461.
53. Bachelot T., Bourgier C., Cropet C., et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. JClin Oncol 2012, 30(22):2718-2724.
54. Awada A., Cardoso F., Fontaine C., et al. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. Eur J Cancer 2008, 44:84-91.
55. Baselga J., Semiglazov V., van Dam P., et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. JClin Oncol 2009, 27(16):2630-2637.